Patient Reported Outcomes’ Influence on Pre-Launch Activities

Patient Reported Outcomes’ Influence on Pre-Launch Activities

Q1’s 4th Annual Pharma & Biotech Medical Affairs Pre-Launch Strategies Conference features an array of payer, legal and industry perspectives, including Ann Leon of CSL Behring. Learn about her experience and upcoming session below!   Can you please give a...
Mapping KOL Relationships

Mapping KOL Relationships

Q1’s 4th Annual Pharma & Biotech Medical Affairs Pre-Launch Strategies Conference taking place on April 29-30 features a mix of industry perspectives from experts, including Daniel Snyder of Revance Therapeutics, Inc. His session, “KOL Mapping: Innovative...
How One Company is Redefining Scientific Exchange

How One Company is Redefining Scientific Exchange

Digital Medical Affairs How One Company is Redefining Scientific Exchange How One Company is Redefining Scientific Exchange   Scientific exchange is an integral part of the pre-launch phase for medical affairs. Traditionally, this information is deployed to...

Building the Pre-Launch Road-Map

Building the Pre-Launch Road-Map Expert Tips for Navigating the Pre-Launch Phase Expert Tips for Navigating the Pre-Launch Phase       Evolving complexities and increased scrutiny of the pharmaceutical industry have dictated a heavy reliance on early...
Redefining the Pre-Launch MSL

Redefining the Pre-Launch MSL

Redefining the Pre-Launch MSL Redefining the Pre-Launch MSL Recent changes to healthcare have dictated equal and necessary changes to the product launch process. As the healthcare industry shifts towards patient-centered care, new standards have been placed on the way...